PD-1 inhibitors can bind to PD-1 receptors and block their interaction with PD-L1 and PD-L2, thus releasing the suppression of immune responses mediated by the PD-1 pathway, including anti-tumor immune responses, and enabling the immune system to better attack and kill tumor cells. Here, PDCD1LG2 is linked to neoplasm.